March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Impact of PROSE Treatment of the Ocular Sequelae of Stevens-Johnson Syndrome
Author Affiliations & Notes
  • Hong-Gam Le
    Boston Foundation for Sight, Needham, Massachusetts
  • Deborah S. Jacobs
    Boston Foundation for Sight, Needham, Massachusetts
    Ophthalmology, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  Hong-Gam Le, None; Deborah S. Jacobs, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4717. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hong-Gam Le, Deborah S. Jacobs; Impact of PROSE Treatment of the Ocular Sequelae of Stevens-Johnson Syndrome. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4717. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To study the impact of prosthetic replacement of the ocular surface ecosystem (PROSE) treatment in patients with history of Stevens-Johnson syndrome.

Methods: : A manufacturing database of patients treated at this center was sorted by diagnosis. Retrospective medical record review of patients with diagnosis of Stevens-Johnson syndrome (SJS) was undertaken. Number of patients with history of SJS for whom PROSE treatment was initiated by year, gender, and age at referral are reported. Beginning in 2006, NEI VFQ-25 was administered to patients at initial consultation for PROSE treatment. Baseline Composite NEI VFQ-25 score and Self-Reported General Health score, and changes in these scores at 6 months, in a 5 year cohort from 2006 to 2010 are compared by t-test.

Results: : 235 patients with ocular SJS were referred for PROSE treatment from 1987 through 2010. M: F = 89:146. Mean age at referral is 30 years ±17, range 4 -79. One patient with ocular SJS was treated with a PROSE device in 1987; 32 new patients with this diagnosis were treated in 2010. Among patients seen since 2006, mean baseline NEI VFQ-25 was 48 pts (n = 100). Significant improvement in visual function was observed in these patients (mean improvement = 23pts, n=83, p = 1.04566E-17). Less significant improvement in Self-Reported General Health score was observed (mean improvement = 8pts, n = 83, p = 0.005). Impact on visual acuity will be reported.

Conclusions: : PROSE treatment has significant positive impact on visual function of patients with history of SJS. Further review and analysis of data from medical records of these patients treated over the past two decades could contribute to our understanding of the natural history of the ocular sequelae of SJS in patients referred for PROSE treatment.

Keywords: contact lens • cornea: tears/tear film/dry eye • clinical (human) or epidemiologic studies: natural history 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.